Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths

Rationale and Objectives:To characterize and compare commercially available contrast media (CM) for magnetic resonance imaging (MRI) in terms of their relaxivity at magnetic field strengths ranging from 0.47 T to 4.7 T at physiological temperatures in water and in plasma. Relaxivities also were quantified in whole blood at1.5 T. Methods:Relaxivities of MRI-CM were determined by nuclear magnetic resonance (NMR) spectroscopy at 0.47 T and MRI phantom measurements at 1.5 T, 3 T, and 4.7 T, respectively. Both longitudinal (T1) and transverse relaxation times (T2) were measured by appropriate spin-echo sequences. Nuclear magnetic resonance dispersion (NMRD) profiles were also determined for all agents in water and in plasma. Results:Significant dependencies of relaxivities on the field strength and solvents were quantified. Protein binding leads to both increased field strength and solvent dependencies and hence to significantly altered T1 relaxivity values at higher magnetic field strengths. Conclusions:Awareness of the field strength and solvent associated with relaxivity data is crucial for the comparison and evaluation of relaxivity values. Data observed at 0.47 T can thus be misleading and should be replaced by relaxivities measured at 1.5 T and at 3 T in plasma at physiological temperature.

[1]  J. Felblinger,et al.  Renal Functional Contrast-Enhanced Magnetic Resonance Imaging: Evaluation of a New Rapid-Clearance Blood Pool Agent (P792) in Sprague-Dawley Rats , 2005, Investigative radiology.

[2]  Bernd Hamm,et al.  Comparison of the Iron Oxide-Based Blood-Pool Contrast Medium VSOP-C184 With Gadopentetate Dimeglumine for First-Pass Magnetic Resonance Angiography of the Aorta and Renal Arteries in Pigs , 2004, Investigative radiology.

[3]  Atle Bjørnerud,et al.  In and Ex Vivo MR Evaluation of Acute Myocardial Ischemia in Pigs by Determining R1 in Steady State After the Administration of the Intravascular Contrast Agent NC100150 Injection , 2004, Investigative radiology.

[4]  B. Hamm,et al.  Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.

[5]  A. Huppertz,et al.  Gadobutrol, a highly concentrated MR imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and in perfusion imaging , 2004, European radiology.

[6]  Michael Bock,et al.  Contrast-Enhanced Three-Dimensional Pulmonary Perfusion Magnetic Resonance Imaging: Intraindividual Comparison of 1.0 M Gadobutrol and 0.5 M Gd-DTPA at Three Dose Levels , 2004, Investigative radiology.

[7]  J. Debatin,et al.  Using a 1 M Gd‐chelate (gadobutrol) for total‐body three‐dimensional MR angiography: Preliminary experience , 2003, Journal of magnetic resonance imaging : JMRI.

[8]  Wolfgang Ebert,et al.  Tissue-specific MR contrast agents. , 2003, European journal of radiology.

[9]  J. Debatin,et al.  Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance Angiography , 2003, Investigative radiology.

[10]  Peter Caravan,et al.  The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.

[11]  M. Leach,et al.  The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. , 2002, Physics in medicine and biology.

[12]  A. Bjørnerud,et al.  Renal T  *2 perfusion using an iron oxide nanoparticle contrast agent—influence of T1 relaxation on the first‐pass response , 2002, Magnetic resonance in medicine.

[13]  T. Frenzel,et al.  Comparative studies on the efficacy of MRI contrast agents in MRA. , 2002, Academic radiology.

[14]  L. Calabi,et al.  The problematic determination of proton magnetic relaxation rates of protein-containing solutions. , 2002, Academic radiology.

[15]  W. Heindel,et al.  Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol , 2002, European Radiology.

[16]  W. Yuh,et al.  A Clinical Comparison of the Safety and Efficacy of MultiHance (Gadobenate Dimeglumine) and Omniscan (Gadodiamide) in Magnetic Resonance Imaging in Patients with Central Nervous System Pathology , 2001, Investigative radiology.

[17]  A. Bjørnerud,et al.  NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.

[18]  S. Schoenberg,et al.  Contrast agents for MRA: Future directions , 1999, Journal of magnetic resonance imaging : JMRI.

[19]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[20]  S. H. Koenig,et al.  NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. , 1999, Investigative radiology.

[21]  D. Bluemke,et al.  New MR imaging contrast agents. , 1999, Magnetic resonance imaging clinics of North America.

[22]  S B Reeder,et al.  Effects of water exchange on the measurement of myocardial perfusion using paramagnetic contrast agents , 1999, Magnetic resonance in medicine.

[23]  P. A. Rinck,et al.  Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents , 1999, European Radiology.

[24]  C. Marx,et al.  T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging. , 1998, Radiology.

[25]  S. Laurent,et al.  Multinuclear magnetic resonance characterization of paramagnetic contrast agents. The manifold effects of concentration and counterions. , 1998, Investigative radiology.

[26]  A. Spinazzi,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[27]  W. Yuh,et al.  Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine. , 1998, Academic radiology.

[28]  C. Cotman,et al.  Magnetic resonance imaging relaxation times and gadolinium-DTPA relaxivity values in human cerebrospinal fluid. , 1998, Investigative radiology.

[29]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[30]  A. Elster.  How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence , 1997, European Radiology.

[31]  I. Bertini,et al.  NMR of paramagnetic substances , 1996 .

[32]  H. Weinmann,et al.  Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. , 1995, European journal of radiology.

[33]  V. Runge,et al.  Update: Safety, New Applications, New MR Agents , 1995, Topics in magnetic resonance imaging : TMRI.

[34]  W J Manning,et al.  Studies of Gd‐DTPA relaxivity and proton exchange rates in tissue , 1994, Magnetic resonance in medicine.

[35]  T. Hilbertz,et al.  Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. , 1992, AJNR. American journal of neuroradiology.

[36]  H. Weinmann,et al.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. , 1992, Radiology.

[37]  T. Vogl,et al.  Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients. , 1992, Radiology.

[38]  A. Roch,et al.  Transverse relaxivity of particulate MRI contrast media: From theories to experiments , 1991, Magnetic resonance in medicine.

[39]  I. Bertini,et al.  Nuclear and Electron Relaxation: The Magnetic Nucleus-Unpaired Electron Coupling in Solution , 1991 .

[40]  V. Runge,et al.  Phase III clinical evaluation of Gd‐HP‐DO3A in head and spine disease , 1991, Journal of magnetic resonance imaging : JMRI.

[41]  G. Elizondo,et al.  Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. , 1991, Radiology.

[42]  S. Quay,et al.  Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection. , 1990, Investigative radiology.

[43]  N. Juul,et al.  Doctors' requirements for reproducibility of diagnostic information. , 1990, Investigative radiology.

[44]  V M Runge,et al.  Gd DTPA: a review of clinical indications in central nervous system magnetic resonance imaging. , 1989, Radiographics : a review publication of the Radiological Society of North America, Inc.

[45]  R. Lauffer,et al.  Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .

[46]  W. Semmler,et al.  Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. , 1987, AJNR. American journal of neuroradiology.

[47]  M. Brechbiel,et al.  Gd(DOTA): An alternative to Gd(DTPA) as a T1,2 relaxation agent for NMR imaging or spectroscopy , 1986, Magnetic resonance in medicine.

[48]  R. Felix,et al.  Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. , 1985, AJNR. American journal of neuroradiology.

[49]  G. Bydder,et al.  INTRAVENOUS CHELATED GADOLINIUM AS A CONTRAST AGENT IN NMR IMAGING OF CEREBRAL TUMOURS , 1984, The Lancet.

[50]  R. Brasch,et al.  Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.

[51]  J. Douglas,et al.  Value of 1 , 1982 .

[52]  J L Potter,et al.  NMR relaxation of protons in tissues and other macromolecular water solutions. , 1982, Magnetic resonance imaging.

[53]  G. C. Levy.  Topics in carbon-13 NMR spectroscopy , 1974 .

[54]  Thomas C. Farrar,et al.  Pulse and Fourier transform NMR , 1971 .

[55]  A. D. McLachlan,et al.  Introduction to magnetic resonance : with applications to chemistry and chemical physics , 1967 .

[56]  Nicolaas Bloembergen,et al.  Proton Relaxation Times in Paramagnetic Solutions. Effects of Electron Spin Relaxation , 1961 .

[57]  Nicolaas Bloembergen,et al.  Proton Relaxation Times in Paramagnetic Solutions , 1957 .

[58]  R. Coombs,et al.  Modification of human red cells by virus action; agglutination by incomplete Rh antibody. , 1947, Lancet.